2025-03-31 18:39:34
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Bliss GVS Pharma Ltd Q2FY22 consolidated net profit slips QoQ to Rs. 21.26 crore
Posted On : 2021-11-04 20:57:25( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended September 30, 2021.
Financial Results (Q2 FY2022) - QoQ Comparison
The company has reported total income of Rs. 201.4374 crores during the period ended September 30, 2021 as compared to Rs. 175.9626 crores during the period ended June 30, 2021.
The company has posted net profit / (loss) of Rs. 21.2662 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs. 24.2542 crores for the period ended June 30, 2021.
The company has reported EPS of Rs. 2.01 for the period ended September 30, 2021 as compared to Rs. 2.29 for the period ended June 30, 2021.
| Financials | Q2 FY2022 | Q1 FY2022 | % Change |
| Total Income | ₹ 201.4374 crs | ₹175.9626 crs |  14.48% |
| Net Profit | ₹21.2662 crs | ₹24.2542 crs |  -12.32% |
| EPS | ₹2.01 | ₹2.29 | -12.23% |
Financial Results (Q2 FY2022) - YoY Comparison
The company has reported total income of Rs. 201.4374 crores during the period ended September 30, 2021 as compared to Rs.136.5915 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.21.2662 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs.16.1920 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.2.01 for the period ended September 30, 2021 as compared to Rs.1.54 for the period ended September 30, 2020.
| Financials | Q2 FY2022 | Q2 FY2021 | % Change |
| Total Income | ₹ 201.4374 crs | ₹136.5915 crs | 47.47% |
| Net Profit | ₹21.2662 crs | ₹16.1920 crs | 31.34% |
| EPS | ₹2.01 | ₹1.54 | 30.52% |
Financial Results (Half Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.377.40 crores during the 6 Months period ended September 30, 2021 as compared to Rs.290.8731 crores during the 6 Months period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.45.5204 crores for the 6 Months period ended September 30, 2021 as against net profit / (loss) of Rs.36.6982 crores for the 6 Months period ended September 30, 2020.
The company has reported EPS of Rs.4.30 for the 6 Months period ended September 30, 2021 as compared to Rs.3.48 for the 6 Months period ended September 30, 2020.
| Financials | Half Year Ended FY2022 | Half Year Ended FY2021 | % Change |
| Total Income | ₹377.40 crs | ₹290.8731 crs | 29.75% |
| Net Profit | ₹45.5204 crs | ₹36.6982 crs | 24.04% |
| EPS | ₹4.30 | ₹3.48 | 23.56% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 105.90 as compared to the previous close of Rs. 107.50. The total number of shares traded during the day was 22012 in over 583 trades.
The stock hit an intraday high of Rs. 108.55 and intraday low of 105.65. The net turnover during the day was Rs. 2351641.00.
